Efficacy of pravastatin in non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI)-based HAART in HIV-infected patients

American Journal of Infectious Diseases

Volumn 4, Issue 2, 2008, Pages 124-130

  Eaton, Susan A ^a   Rahman, Anita P ^a   Nguyen, Sean T ^a   Baia, Amy M ^a   Payne, Kenna D ^a   Busti, Anthony J ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Highly active antiretroviral therapy; Lipids; Statins

Indexed keywords

CHOLESTEROL; EFAVIRENZ; LOW DENSITY LIPOPROTEIN; NEVIRAPINE; PRAVASTATIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPROTEIN BLOOD LEVEL; MALE; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

EID: 41149108996     PISSN: 15536203     EISSN: None     Source Type: Journal    
DOI: 10.3844/ajidsp.2008.124.130     Document Type: Article

References (18)

1. Mocroft, A., R. Brettle, O. Kirk, A. Blaxhult, J.M. Parkin, F. Antunes, P. Francioli, A. D'Arminio Monforte, Z. Fox and J.D. Lungren, 2002. Changes in the cause of death among HIV positive subjects across Europe: Results from EuroSIDA study. AIDS, 16: 1663-1671.
2. Palella, F.J., K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, D.J. Aschman and S.D. Holmberg, 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med., 338: 853-860.
3. DAD Study Group, 2007. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med., 356: 1723-1735.
4. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults, 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285: 2486-2497.
5. Dube, M.P., J.H. Stein, J.A. Aberg, C.J. Fitchenbaum, J.G. Gerber, K.T. Tashima, K.W. Henry, J.S. Currier, D. Sprecher and M.J. Glesby, 2003. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV medicine association of the Infectious Disease Society of America and the Adult Aids Clinical Trials Group. Clin. Infect. Dis., 37: 613-627.
6. Lennernas, H. and, G. Fager, 1997. Pharmacodynamic and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet., 32: 403-425.
7. Gerber, J.G., S.L. Rosenkranz, C.J. Fichentenbaum, J.M. Vega, A. Yang, B.L. Alston, S.W. Brobst, Y. Segal and J.A. Aber, 2005. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin and pravastatin. J. Acquir. Immune. Defic. Syndr., 39-307-312.
8. Fichentenbaum, C.J., J.G. Gerber, S.L. Rosenkranz, Y. Segal. J.A. Aber, T. Blaschke, B. Alston, F. Fang, B. Kosel and F. Aweeka, 2002. Pharmacokinetic interactions between protease inhibitors and statins in HIV sero-negative volunteers: ACTG Study A5047. AIDS, 16:569-57/.
9. Neuvonen, P.J., N. Mikko and J.T. Backman, 2006. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin. Pharmacol. Ther., 80, 565-581.
10. Stormer, E., L.L. von Moltke, M.D. Perloff and D.J. Greenblatt, 2002. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm. Res., 19: 1038-1045.
11. Chandia, P. and K.L. Brouwer, 2004. The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharm. Res., 21: 719-735.
12. Erickson, D.A., G. Mather, W.F. Trager, R.H. Levy and J.J. Keirns, 1999. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug. Metab. Dispos., 27: 1488-1495.
13. Piscitelli, S.C. and K.D. Gallicano, 2001. Interactions among drugs for HIV and opportunistic infections. N. Engl. J. Med., 344: 984-996.
14. Riska, P., M. Lamson, T: MacGregor, J. Sabo, S. Hattox, J. Pav and J. Keirns, 1999. Disoposition and biotransformation of the antiretroviial drug nevirapinein humans. Drug Metab. Dispos. 8; 895-901.
15. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. October 10, 2006; 1-113. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentsGL.pdf. Accessed (July 2, 2007).
16. Ouellet, D., A. Hsu, J. Qian, C.S. Locke, C.J. Eason, J.H. Cavanaugh, J.M. Leonard and G.R. Granneman, 1998. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female Volunteers. Br. J. Clin. Pharmacol., 2: 111-116.
17. Pravastatin (Pravachol®) Product insert. Bristol-Myers Squibb, Inc., Princeton, NJ. April 2007.
18. Jones, P.H., M.H. Davidson, E.A. Stein, H.E. Bays, J.M. Mckenney, E. Miller, V.A. Cain and J.W. Biasetto, 2003. Comparison of the efficacy and safety of rosuvstatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial). Am. J. Card., 93: 152-160.